What is type 1 diabetes mellitus and how is it managed?

Type 1 Diabetes Mellitus and Its Management

Type 1 diabetes mellitus is an autoimmune disease causing pancreatic β-cell destruction and absolute insulin deficiency, requiring lifelong insulin replacement therapy as the cornerstone of treatment, with intensive insulin regimens (multiple daily injections or insulin pump therapy) combined with frequent glucose monitoring to prevent both acute complications like ketoacidosis and long-term microvascular and macrovascular complications. 1, 2

What is Type 1 Diabetes?

Type 1 diabetes accounts for 5-10% of all diabetes cases and affects approximately 2 million people in the US and 8.4 million worldwide 2. It results from autoimmune destruction of insulin-producing β-cells in the pancreas, leading to absolute insulin deficiency and hyperglycemia 2, 3.

Key diagnostic features:

• 90-95% of patients have at least one islet autoantibody at diagnosis (insulin autoantibodies, GAD65, IA-2, or ZnT8) - these are absent in type 2 or monogenic diabetes 2, 3
• Autoantibodies appear months to years before symptoms develop, allowing identification of at-risk individuals 3
• Median age of diagnosis is 24 years in the US, though most commonly diagnosed between ages 10-14 years 2
• Up to 44% of children and 23% of adults present with diabetic ketoacidosis at diagnosis 2

Insulin Therapy: The Foundation of Treatment

Insulin is the absolute basis of therapy for type 1 diabetes 1. The intensive insulin regimens proven to reduce complications include either multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) via insulin pump 1.

Starting Insulin Dosing

Initial total daily insulin dose: 0.5 units/kg body weight for metabolically stable patients (range 0.4-1.0 units/kg) 1. Higher doses may be needed for:

• Patients presenting with diabetic ketoacidosis
• Adolescents during puberty

Standard distribution: 50% basal insulin + 50% bolus insulin 4

Insulin Regimen Components

Basal insulin (long-acting analogues):

• Glargine or degludec administered once to twice daily 2
• Provides background insulin coverage

Bolus insulin (rapid-acting analogues):

• Aspart or lispro administered before meals containing carbohydrates 2
• Also used to correct hyperglycemia
• Timing should be individualized based on insulin type, current glucose level, meal timing, and carbohydrate content 1

Critical advantage of modern insulin analogues: Rapid-acting and long-acting insulin analogues are associated with less hypoglycemia compared to older human insulins while achieving equivalent HbA1c improvements 1. This is crucial since the DCCT trial showed intensive therapy with human insulin caused 61 episodes of severe hypoglycemia per 100 patient-years 1.

Advanced Insulin Delivery

Continuous subcutaneous insulin infusion (CSII) via insulin pump shows modest superiority over MDI:

• Meta-analysis demonstrated HbA1c reduction of 0.30 percentage points favoring CSII 1
• Reduced severe hypoglycemia rates in children and adults 1

Hybrid closed-loop systems (automated insulin delivery): These systems automatically adjust basal insulin rates based on continuous glucose monitoring data 1, 2. Randomized trials demonstrate less hypoglycemia and improved HbA1c levels, with greatest improvement in those starting with HbA1c >8.0% 2.

Glucose Monitoring: Essential for Safety and Control

Self-Monitoring Blood Glucose (SMBG)

Patients on intensive insulin regimens should test:

• Before all meals and snacks
• At bedtime
• When suspecting hypoglycemia
• After treating hypoglycemia until normoglycemic
• Before exercise and critical tasks like driving
• Occasionally after meals 1

This typically requires 6-10 or more tests daily 1. Frequent SMBG is associated with lower HbA1c levels in both clinical trials and observational studies 1.

Continuous Glucose Monitoring (CGM)

CGM in conjunction with intensive insulin regimens lowers HbA1c levels in adults aged ≥25 years (A-level evidence) 1.

Specific indications for CGM:

• Patients with hypoglycemia unawareness 1
• Frequent hypoglycemic episodes 1
• Those seeking optimal glucose control

Critical implementation requirement: Robust diabetes education, training, and ongoing support are mandatory for optimal CGM use 1. Access should continue after age 65 for successful users 1.

Patient Education: Non-Negotiable Component

All patients must be referred to:

• Diabetes self-management education program 4
• Medical nutrition therapy (can lower HbA1c by up to 1.9% in type 1 diabetes) 4

Essential education topics:

• Carbohydrate counting to match prandial insulin dosing 1
• For advanced patients: fat and protein gram estimation 1
• Recognition and treatment of hypoglycemia
• Sick day management
• Exercise adjustments

Hypoglycemia Management: The Major Limiting Factor

Hypoglycemia is the major limiting factor in glycemic management of type 1 diabetes 1. It can progress to loss of consciousness, seizure, coma, or death, and causes acute harm through falls and motor vehicle accidents 1.

Hypoglycemia Treatment Protocol

For conscious patients with glucose ≤70 mg/dL (3.9 mmol/L):

1. Administer 15-20 grams of glucose (preferred treatment) or any carbohydrate containing glucose 1
2. Recheck glucose in 15 minutes
3. Repeat treatment if still hypoglycemic
4. Once normal, consume a meal or snack to prevent recurrence 1

For severe hypoglycemia (unconscious or unable to take oral carbohydrates):

• Glucagon must be prescribed to all patients at increased risk (glucose <54 mg/dL or 3.0 mmol/L) 1
• Family members, roommates, school personnel, child care providers, and coworkers must be trained in glucagon administration 1

Hypoglycemia Unawareness Management

For patients with hypoglycemia unawareness or clinically significant hypoglycemia:

• Raise glycemic targets to strictly avoid hypoglycemia for at least several weeks (A-level evidence) 1
• This partially reverses hypoglycemia unawareness and reduces future episode risk 1

High-Risk Situations for Hypoglycemia

Educate patients about increased risk during:

• Fasting for tests
• Delayed meals
• During or after exercise
• During sleep
• While driving (keep glucose meter and rapid-acting glucose in car) 1

Assess for symptomatic and asymptomatic hypoglycemia at every encounter 1.

Adjunctive Therapies

FDA-Approved Adjunct: Pramlintide

Pramlintide is the only FDA-approved adjunct to insulin for type 1 diabetes 1, 4. It is an injectable amylin analogue indicated for patients not achieving glucose goals despite optimized insulin therapy.

Mechanism:

• Delays gastric emptying
• Blunts glucagon secretion
• Enhances satiety

Critical caveat: Reduce prandial insulin dosing when initiating pramlintide to minimize severe hypoglycemia risk 1.

Investigational Agents (Not FDA-Approved for Type 1 Diabetes)

Metformin:

• Does NOT lower HbA1c in poorly controlled type 1 diabetes (reduction 0.11 percentage points, P=0.42) 1
• Does reduce insulin requirements by 6.6 units/day and causes small reductions in weight and LDL cholesterol 1

GLP-1 receptor agonist liraglutide:

• Improved HbA1c by 0.34-0.54 percentage points over 52 weeks 1
• Reduced body weight by 2.2-4.9 kg more than placebo 1
• Major safety concerns: 20-30% increase in hypoglycemia rates and 2.2-fold increased risk of hyperglycemia with ketosis at 1.8 mg/day dose 1

SGLT-2 inhibitors:

• FDA warning issued in May 2015: Risk of euglycemic diabetic ketoacidosis 1
• If symptoms develop (dyspnea, nausea, vomiting, abdominal pain), stop immediately and seek medical attention 1

Surgical Options

Pancreas transplantation:

• Normalizes glucose control but requires lifelong immunosuppression 1
• Reserved for patients also receiving renal transplantation or those with recurrent ketoacidosis/severe hypoglycemia despite intensive management 1

Islet transplantation: Remains investigational 1

Monitoring for Complications

Regular screening required for:

• Hypertension 4
• Microvascular complications (retinopathy, nephropathy, neuropathy) 2
• Macrovascular disease (cardiovascular disease) 2
• Other autoimmune diseases (higher risk in type 1 diabetes) 5
• Psychosocial issues 5

Common Pitfalls to Avoid

1. Inadequate hypoglycemia prevention education - This is the #1 barrier to optimal control
2. Failure to prescribe glucagon to all appropriate patients and train caregivers
3. Not adjusting insulin timing based on insulin type and meal composition
4. Insufficient SMBG frequency - Many patients need 6-10+ tests daily
5. Using SGLT-2 inhibitors off-label without discussing euglycemic DKA risk
6. Inadequate patient education and support when prescribing CGM or insulin pumps
7. Not reassessing glycemic targets in patients with hypoglycemia unawareness